Canadian Stocks Fall 0.1%
Dow Jones2026/09/29 20:31This article was automatically generated by Dow Jones using technology from Automated Insights.
Stocks in Canada slipped Tuesday, as the S&P/TSX Composite Index dropped 0.1% to 35460.27.
Among large local companies, WSP Global was the biggest laggard, tumbling 5.6%, followed by shares of Savaria, which tumbled 5.4%. Shares of MDA Space dropped 4.1%.
Faraday Copper was the biggest leader during the session, gaining 3.9%, and Badger Infr Solns rose 3.9%. Highlander Silver rounded out the top three movers, as shares rose 3.8%.
U.S. stock indexes declined with the Dow Jones Industrial Average dropping 0.3%. Meanwhile, the S&P 500 Index declined 0.2%, and the Nasdaq Composite Index declined 0.1%.
On the currency front, the WSJ Dollar Index increased 0.2% to 97.00. The Canadian dollar weakened 0.1% against the U.S. dollar to US$0.70.
In the bond markets, the 10-year Canadian government bond yield rose 3.14 basis points to 3.997%.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 29, 2026 16:31 ET (20:31 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
